Pharmacological management of high triglycerides and low high-density lipoproetin cholesterol

Current Opinion in Pharmacology

Volumn 1, Issue 2, 2001, Pages 113-120

  Szapary, Philippe O ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Coronary artery disease; Drug Discovery; Epidemiology; Estrogens; Fibrates; HDL cholesterol; HMGCoA reductase inhibitors; Molecular Medicine; Niacin; Omega 3 Fatty acids; Pharmacology; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; CARBOXYLIC ACID; CELL RECEPTOR; FATTY ACIDS, OMEGA 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COA REDUCTASE INHIBITORS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG POTENTIATION; EPIDEMIOLOGY; HEALTH BEHAVIOR; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOLIPOPROTEINEMIA; METABOLISM; PHYSIOLOGY; REVIEW; RISK FACTOR;

ACIDS, ACYCLIC; ANTILIPEMIC AGENTS; CLINICAL TRIALS; CORONARY DISEASE; EPIDEMIOLOGIC STUDIES; FATTY ACIDS, OMEGA-3; HEALTH BEHAVIOR; HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOLIPOPROTEINEMIA; LIPOPROTEINS, HDL CHOLESTEROL; NIACIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0035317950     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00028-5     Document Type: Review

References (58)

1. Grundy S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation. 97:1998;1436-1439.
2. Gould L.A., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 97:1998;946-952.
3. Tall A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 86:1990;379-384.
4. Rader D.J., Ikewaki K. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol. 7:1996;117-123.
5. Hobbs H.H., Rader D.J. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest. 104:1999;1015-1017.
6. Krieger M. The 'best' of cholesterols, the 'worst' of cholesterols: a tale of two receptors. Proc Natl Acad Sci USA. 95:1998;4077-4080.
7. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 3:1996;213-219.
8. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 97:1998;1029-1036.
9. Assmann G., Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol. 70:1992;10H-13H.
10. Cambien F., Jacqueson A., Richard J.L., Warnet J.M., Ducimetiere P., Claude J.R. Is the level of serum triglyceride a significant predictor of coronary death in 'normocholesterolemic' subjects? The Paris Prospective Study. Am J Epidemiol. 124:1986;624-632.
11. Avins A.L., Neuhaus J.M. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med. 160:2000;1937-1944.
12. Sprecher D.L., Pearce G.L., Cosgrove D.M., Lytle B.W., Loop F.D., Pashkow F.J. Relation of serum triglyceride levels to survival after coronary artery bypass grafting. Am J Cardiol. 86:2000;285-288.
13. Harjai K.J. Potential new cardiovascular risk factors: left ventricular hypertrophy homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med. 131:1999;376-386. This is a nice review of emerging risk factors, which identifies postprandial hypertriglyceridaemia as a novel cardiovascular risk factor.
14. Teno S., Uto Y., Nagashima H., Endoh Y., Iwamoto Y., Omori Y., Takizawa T. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care. 23:2000;1401-1406.
15. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Almeras N., Bergeron J., Gaudet D., Tremblay G., Prud'homme D., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B;metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 102:2000;179-184.
16. Gordon D.J., Rifkind B.M. High-density lipoproteins - the clinical implications of recent studies. N Engl J Med. 321:1989;1311-1316.
17. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 17:1997;107-113.
18. Hegele R.A., Harris S.B., Brunt J.H., Young T.K., Hanley A.J., Zinman B., Connelly P.W. Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis. 146:1999;153-160.
19. Vega G.L., Grundy S.M. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 7:1996;209-216.
20. Glueck C.J., Fallat R.W., Millett F., Gartside P., Elston R.C., Go R.C. Familial hyper-alpha-lipoproteinenia: studies in eighteen kindreds. Metabolism. 24:1975;1243.
21. Bloomfield R.H. The trouble with triglycerides. Arch Intern Med. 160:2000;1903-1904. This is a concise overview of the issues surrounding the value of fasting triglycerides as a cardiovascular risk factor.
22. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedwald W. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 8:1986;1245-1255.
23. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245.
24. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 341:1999;410-418. This is the first trial to show that fibrates reduced mortality in patients with recognized coronary artery disease.
25. The Bezafibrate Infarction Prevention (BIP) study: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000, 102:21-27.In the trial described here, a fibrate did not statistically significantly reduce coronary events in this high-risk population.
26. Tenkanen L., Pietila K., Manninen V., Manttari M. The triglyceride issue revisited. Findings from the Helsinki heart study. Arch Intern Med. 154:1994;2714-2720.
27. Gotto A.M. Cholesterol management in theory and practice. Circulation. 96:1997;4424-4430.
28. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69B.
29. Stein E., Plotkin D., Bays H., Davidson M., Dujovne C., Korenman S., Stepanavage M., Mercuri M. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 86:2000;406-411.
30. Crouse JR III, Frohlich J, Ose L, Mercuri M, Tobert JA: Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 83:1476-1477.
31. Kastelein J.J., Isaacsohn J.L., Ose L., Hunninghake D.B., Frohlich J., Davidson M.H., Habib R., Dujovne C.A., Crouse J.R., Liu M., et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 86:2000;221-223. This study compared two potent statins head to head, and suggested that 80mg of simvastatin had a more potent HDL-cholesterol-raising effect than 40mg of atorvastatin.
32. Rader D.J., Haffner S.M. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol. 83:1999;30F-35F.
33. Bays H.E., Dujovne C.A. Drug interactions of lipid-altering drugs. Drug Safety. 19:1998;355-371.
34. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., Brody J. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 82:1998;74U-81U.
35. Goldberg A., Alagona P. Jr, Capuzzi D.M., Guyton J., Morgan J.M., Rodgers J., Sachson R., Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 85:2000;1100-1105.
36. The coronary drug project research group: Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975, 231:360-381.
37. McKenney J.M., Proctor J.D., Harris S., Chinchili V.M. A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc. 271:1994;672-677.
38. Morgan J.M., Capuzzi D.M., Guyton J.R., Centor R.M., Goldberg R., Robbins D.C., Dipette D., Jenkins S., Marcovina S. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharm Ther. 1:1996;195-202.
39. Guyton J.R., Blazing M.A., Hagar J., Kashyap M.L., Knopp R.H., McKenney J.M., Nash D.T., Nash S.D. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med. 160:2000;1177-1184. This direct comparison of Niaspan and gemfibrozil points out that while Niaspan was more effective in raising HDL-cholesterol, gemfibrozil was more potent in reducing triglycerides.
40. Elam MB, Hunninghake DB, Davis KB: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. J Am Med Assoc 2000, 284:1263-1270.This study describes the experience of using short acting niacin in a subset of patients with atherosclerotic cardiovascular disease and diabetes. The results suggest that niacin can be used safely in this population, with minimal effect on glycaemic control.
41. O'Keefe J.H. Jr, Harris W.S. From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc. 75:2000;607-614. An excellent review of the role of N3-PUFAs in cardiovascular disease.
42. Harris W.S. N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 31:1996;243-252.
43. Weber P., Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids - a review. Nutr Metab Cardiovasc Dis. 10:2000;28-37.
44. von Schacky C., Angerer P., Kothny W., Theisen K., Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 130:1999;554-562.
45. Eritsland J. Safety considerations of polyunsaturated fatty acids. Am J Clin Nutr. 71:2000;197S-201S.
46. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.This landmark study showed that low dose N3-PUFAs (850 mg/day) reduced triglycerides minimally, but reduced the risk of cardiovascular death by 15% in patients postmyocardial infarction.
47. Stark K.D., Park E.J., Maines V.A., Holub B.J. Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial. Am J Clin Nutr. 72:2000;389-394.
48. Friedberg C.E., Janssen M.J., Heine R.J., Grobbee D.E. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care. 21:1998;494-500.
49. Davidson M.H., Macariola-Coad J.R., McDonald A.M., Maki K.C., Hall H.A. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 80:1997;797-798.
50. Stefanick M.L., Mackey S., Sheehan M., Ellsworth N., Haskell W.L., Wood P.D. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. New Engl J Med. 339:1998;12-20.
51. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995, 273:199-208.
52. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc. 280:1998;605-613.
53. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., Furberg C.D., Kowalchuk G.J., Stuckey T.D., Rogers W.J., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. New Engl J Med. 343:2000;522-529.
54. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993, 269:3015-3023.
55. Knopp R.H. Drug treatment of lipid disorders. New Engl J Med. 341:1999;498-511.
56. Pauciullo P., Borgnino C., Paoletti R., Mariani M., Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis. 150:2000;429-436.
57. Guyton J.R., Capuzzi D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol. 82:1998;82U-84U.
58. Zema M.J. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol. 35:2000;640-646.